Prothena Reports Fourth Quarter and Full Year 2015 Financial Results; Provides Financial Guidance and R&D Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Prothena (PRTA) Pivotal Trial Readout Coming in 2H18 - Wedbush
February 19, 2016 9:47 AM ESTWedbush analyst, Heather Behanna, expects a potential catalyst for Prothena Corp (NASDAQ: PRTA) in 2H18 when data from the VITAL enrollment is released. A slip in the launch date pressures the price target to $77 but the analyst keeps the Outperform rating.
NEOD001 VITAL enrollment update sets up for pivotal trial readout in 2H18. At this time, Prothena anticipates enrollment to be complete in 2Q17 with data to follow in 12-18 months. As a reminder, VITAL is an event driven study enrolling newly diagnosed AL... More
Prothena Corp. (PRTA) Tops Q2 EPS by 5c
February 18, 2016 4:42 PM ESTProthena Corp. (NASDAQ: PRTA) reported Q2 EPS of ($0.76), $0.05 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $307 thousand versus the consensus estimate of $570 thousand.
For earnings history and earnings-related data on Prothena Corp. (PRTA) click here.
... More